INTRODUCTION: Elderly patients with glioblastoma multiforme (GBM) are frequently excluded from cancer therapy trials, treated suboptimally or not treated at all. The average survival in elderly patients is 4-8 months. The goal of the present study was to evaluate the efficacy of different treatment options in terms of survival in an elderly population affected with GBM. MATERIALS AND METHODS: About 34 Patients with primary supratentorial GBM aged 65 or higher were included in this study. All patients underwent craniotomy and tumor mass resection. After surgery they received radiation therapy, chemotherapy and radioimmunotherapy in different combinations. RESULTS: Overall median survival was 10.5 months with one patient still alive at 35 months. Survival was longer for patients who underwent total resection instead of partial (13 months vs 4 months, P=0.006). If total en-bloc resection was used a further survival advantage was obtained (16 months for en-bloc resection, 9 months for inside-out resection, P=0.008). Where a second surgical intervention was performed median survival was 21 months (P=0.05). Survival according to adjuvant therapy has been 21 months (radiotherapy, chemotherapy, radioimmunotheraphy), 18 months (radiotherapy, chemotherapy) and 7 months (radiotherapy) (P=0.0001). CONCLUSIONS: We think that single prognostic factor such as age should be not a reason for undertreatment.
INTRODUCTION: Elderly patients with glioblastoma multiforme (GBM) are frequently excluded from cancer therapy trials, treated suboptimally or not treated at all. The average survival in elderly patients is 4-8 months. The goal of the present study was to evaluate the efficacy of different treatment options in terms of survival in an elderly population affected with GBM. MATERIALS AND METHODS: About 34 Patients with primary supratentorial GBM aged 65 or higher were included in this study. All patients underwent craniotomy and tumor mass resection. After surgery they received radiation therapy, chemotherapy and radioimmunotherapy in different combinations. RESULTS: Overall median survival was 10.5 months with one patient still alive at 35 months. Survival was longer for patients who underwent total resection instead of partial (13 months vs 4 months, P=0.006). If total en-bloc resection was used a further survival advantage was obtained (16 months for en-bloc resection, 9 months for inside-out resection, P=0.008). Where a second surgical intervention was performed median survival was 21 months (P=0.05). Survival according to adjuvant therapy has been 21 months (radiotherapy, chemotherapy, radioimmunotheraphy), 18 months (radiotherapy, chemotherapy) and 7 months (radiotherapy) (P=0.0001). CONCLUSIONS: We think that single prognostic factor such as age should be not a reason for undertreatment.
Authors: J Y Pierga; K Hoang-Xuan; L Feuvret; J M Simon; P Cornu; F Baillet; J J Mazeron; J Y Delattre Journal: J Neurooncol Date: 1999-06 Impact factor: 4.130
Authors: Mark R Gilbert; Henry S Friedman; John F Kuttesch; Michael D Prados; Jeffrey J Olson; Gregory H Reaman; Sara L Zaknoen Journal: Neuro Oncol Date: 2002-10 Impact factor: 12.300
Authors: Nitin Mukerji; Desiderio Rodrigues; Gill Hendry; Peter R C Dunlop; Fiona Warburton; Philip J Kane Journal: J Neurooncol Date: 2007-11-17 Impact factor: 4.130
Authors: Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan Journal: J Neurooncol Date: 2007-05-26 Impact factor: 4.130
Authors: Christopher A Barker; Maria Chang; Joanne F Chou; Zhigang Zhang; Kathryn Beal; Philip H Gutin; Fabio M Iwamoto Journal: J Neurooncol Date: 2012-06-12 Impact factor: 4.130
Authors: Kaisorn L Chaichana; Khan K Chaichana; Alessandro Olivi; Jon D Weingart; Richard Bennett; Henry Brem; Alfredo Quiñones-Hinojosa Journal: J Neurosurg Date: 2010-10-01 Impact factor: 5.115
Authors: Angelique E Sijben; John B McIntyre; Gloria B Roldán; Jacob C Easaw; Elizabeth Yan; Peter A Forsyth; Ian F Parney; Anthony M Magliocco; Hans Bernsen; J Gregory Cairncross Journal: J Neurooncol Date: 2008-04-09 Impact factor: 4.130
Authors: Clark DuMontier; Kah Poh Loh; Paul A Bain; Rebecca A Silliman; Tammy Hshieh; Gregory A Abel; Benjamin Djulbegovic; Jane A Driver; William Dale Journal: J Clin Oncol Date: 2020-04-06 Impact factor: 50.717